Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. - Wikidata - wikimedia - TriplyDB

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34664272

about

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib RAS and BRAF in metastatic colorectal cancer management Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7 The role of MRP1 in the multidrug resistance of colorectal cancer.Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO Report Liver Metastasectomy and Systemic Therapy Improve Overall Survival Compared With Surgery Alone After Curative Liver Resection of Colorectal Metastases in a Developing Country (Costa Rica).Exo70 is an independent prognostic factor in colon cancer.Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab v Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome.Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer.Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.

P2860

Q24658529-766AEAB9-C7A2-41A0-9FE6-1A173C70BA6A Q26738801-CE2C30BC-B9D5-41D3-BAC8-96DD45599BE7 Q26745418-CAF43FB9-720A-45C8-8481-44D6F048D023 Q26774704-AC964A9E-1AAB-4C6C-BBE8-E65F6014B5B6 Q27011366-40681BEA-9D86-44F6-A9B4-728FDF89A5FB Q28068616-32D5FE84-CD72-460B-BA37-528981D803DB Q28074175-B637DC0B-4D07-4521-9495-E3C38E6C26C8 Q28076490-95EBC748-6873-4333-B0B5-530D983D3105 Q28077199-B0102366-E38C-45DA-8DB4-55D7343DE192 Q28084888-F548B123-3613-40AE-9F1A-A201409BA254 Q29398488-8192452C-7622-427B-A5E7-0673E1024715 Q30238915-2ABE7396-8903-409D-B012-19BB3C2A06A6 Q30313818-91D5D361-BC31-492D-A9DC-1D7B2EBC6E95 Q30854226-75B18BA8-CEF9-4710-9C08-C759F3BCC224 Q30855372-980A10C4-A61A-4952-9E5E-A3219A54317F Q31131324-F1B30FE6-34F5-43BB-AFA6-80B124057CB8 Q33441453-B52B3D62-CA54-471E-A658-448AC3880600 Q33563310-0B2069AE-9C19-4971-AC26-38F2231F5B68 Q33598067-7655383C-3E25-4524-8C41-E7449A5C4AF8 Q33751551-49FA888B-4884-496D-8F07-9E62B59D7E6A Q33776697-4D191DBD-65DA-42AA-B8B2-F5C9C04F14BE Q33832740-B431DD8F-A2C5-4F95-B29C-5A700D9A8576 Q33859578-FA7A09D4-02D0-43CB-BC46-C5486F862691 Q33894800-20DB61F2-EC9A-4F66-AFC6-BF7F399957F2 Q34492273-1160641F-C31A-4AEB-BDEC-A4B007C3EE04 Q34547844-2C3D48C5-0DEC-4FDE-A25A-375FDE752F27 Q35535424-1B6C825D-918A-4FF2-BD1A-7D50202CC9A9 Q35666148-CC966191-1D00-40DB-B7A8-2B80547B7452 Q35668071-AEC40DF9-C79E-4209-B6F5-3F690534ED45 Q35674250-88325B24-366F-4994-BEFC-A9EFABD56973 Q35685684-0DA58B27-59E7-4B1D-ACC2-7BACB691FDA0 Q35828499-E8BD2F55-D1CA-4363-BA2E-EB239DA1A8F7 Q35877954-A65A55CB-2DCA-42DA-94DD-D981EC9716F6 Q35920292-F3EED9EC-D5B7-40E2-9810-5F0BE6F80D74 Q36009386-A0F864E7-9D9C-4B87-87F9-75A25A15BB16 Q36050510-22684DB3-3D39-4D5A-9220-47BF6BEC6EF0 Q36083302-769D7FED-A038-4DAE-BB21-677C364DC13A Q36112303-40737A49-6ACC-474B-8E0D-56BD2F0B00D8 Q36148358-29DCCD20-93AA-42E8-B275-7626A4EFF418 Q36281629-80ACEB55-8041-48F2-9CC7-16095E4CCB54

P2860

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34664272

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@ast

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@en

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@nl

type

label

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@ast

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@en

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@nl

prefLabel

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@ast

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@en

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@nl

P1433

Q34664272-915D155B-DE1C-4400-B6D7-8ADD1549A9BD

P1476

Q34664272-7EB74B1A-E9FD-4E8B-9510-1CEDDDE1D427

P2093

Q34664272-95DDF464-D963-4288-969E-24BCCC0C6BC6

Q34664272-9E2A6021-185F-4974-9AD7-4CA28E0B6531

Q34664272-CC065C5C-C6D5-4158-BBC3-307911A058DC

Q34664272-F2DA45D8-66F7-4A7E-A350-54017999BFEB

P2860

Q34664272-046CF2A3-6302-4A72-8524-F967600D696A

Q34664272-0741D6AC-934D-4145-AF29-1BACEC3BBAD5

Q34664272-1593FB45-9714-4343-8167-D149472EF720

Q34664272-1CACD98B-2B69-4755-A791-7602848EE3C1

Q34664272-1F3306DD-CC65-477E-A059-43CC37DFB55B

Q34664272-1F9E5969-558B-4EAB-AC75-BBCAB24D7338

Q34664272-240D5FF0-2115-4CE5-B75C-EFAF7EC5B77B

Q34664272-24A03EC8-9D1F-4A57-AEE9-EAE90D898826

Q34664272-2A4C79D9-6121-4797-A8F2-A4B667550F47

Q34664272-33256C16-B2EF-41CB-A276-AAEAF5E11370

P304

Q34664272-5CCBD385-DCD4-4029-B39C-F77BDB727E86

P31

Q34664272-D7061C19-3ED5-4C03-B562-63815A0F18F7

P356

Q34664272-7AB9A43E-E56E-4EB7-850D-E059B94332C0

P478

Q34664272-3E4C3C0B-7D54-42E2-B713-4DF8D885D3FD

P50

Q34664272-F9F6DF99-4763-49A9-A29D-8D449C654D6D

P577

Q34664272-0D4B9D61-7C86-45C3-B72A-C4D558B8F440

P5875

Q34664272-B56EAE24-A0FE-4135-8D49-47FC619DC0D6

P698

Q34664272-F06FC170-9D2B-4FC5-8ABF-BF65ADBD8C6B

P921

Q34664272-952B562A-D08C-4700-97AA-DA933DB83589

Q34664272-e977f263-18ab-4a7f-a7e7-550b1055f84e

P356

P1433

Annals of Oncology

P1476

Metastatic colorectal cancer: ...... osis, treatment and follow-up.

@en

P2093

A Cervantes

http://www.w3.org/2001/XMLSchema#string

B Nordlinger

http://www.w3.org/2001/XMLSchema#string

E Van Cutsem

http://www.w3.org/2001/XMLSchema#string

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

P2860

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

P304

iii1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU260

http://www.w3.org/2001/XMLSchema#string

P478

25 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265393492

http://www.w3.org/2001/XMLSchema#string

P698

25190710

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer